



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JC18 Rec'd PCT/PTO 31 DEC 2001

5022
Debtse **PATENT**

In re Application of
RHOLAM ET AL.

Examiner: UNASSIGNED

Serial No.: **09/701,945**

Art Unit: UNASSIGNED

Filed: **DECEMBER 5, 2000**

Title: **POLYPEPTIDES WHICH POSSESS
AN ACTIVITY OF THE β -
SECRETASE TYPE**

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents
Washington, D.C. 20231

Sir:


In furtherance of requirements set forth in 37 C.F.R. 1.56, 1.97 AND 1.98 Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- ☒ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the

Commissioner thORIZED to charge any fees under 3 .R. 1.17(p) or credit any
overpayment to Account No. **18-1982**.

- ☐ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☐ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.


Respectfully submitted,



William C. Coppola, Reg. No. 41,686
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-4854
Telefax (908) 231-2626

Attorney Docket No.: ST98014A
October 30, 2001



Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p>			<p>Complete if Known</p> <table border="1"> <tr> <td>Application Number</td> <td>9/701,945</td> </tr> <tr> <td>Filing Date</td> <td>12-05-2000</td> </tr> <tr> <td>First Named Inventor</td> <td>RHOLAM</td> </tr> <tr> <td>Group Art Unit</td> <td></td> </tr> <tr> <td>Examiner Name</td> <td></td> </tr> <tr> <td>Attorney Docket Number</td> <td>ST98014 <i>A</i></td> </tr> </table>		Application Number	9/701,945	Filing Date	12-05-2000	First Named Inventor	RHOLAM	Group Art Unit		Examiner Name		Attorney Docket Number	ST98014 <i>A</i>
Application Number	9/701,945															
Filing Date	12-05-2000															
First Named Inventor	RHOLAM															
Group Art Unit																
Examiner Name																
Attorney Docket Number	ST98014 <i>A</i>															
Sheet	1	of	2													

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-96)
 Approved for use through 10/31/99. OMB 0651-0031
 Patent and Trademark U.S. DEPARTMENT OF COMMERCE
 collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	9/701,945
Filing Date	12-05-2000
First Named Inventor	RHOLAM
Group Art Unit	
Examiner Name	

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

[illegible]

Examiner
Signature

Date
Considered

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.